Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that are focused on mental health.
Castle Biosciences to Acquire AltheaDx
![thehealthco](https://thehealthco.info/wp-content/uploads/2022/04/Castle-Biosciences-to-Acquire-AltheaDx.jpg)